| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 21,061 | 9,410 | ||
| Prepaid expenses | 1,511 | 1,589 | ||
| Other current assets | 77 | 82 | ||
| Total current assets | 22,649 | 11,081 | ||
| Property and equipment, net | 384 | 432 | ||
| Operating lease right-of-use asset | 3,963 | 4,111 | ||
| Total assets | 26,996 | 15,624 | ||
| Accounts payable and other accrued liabilities | 2,219 | 2,903 | ||
| Accrued compensation | 1,901 | 1,040 | ||
| Other current liabilities | 1,494 | 948 | ||
| Total current liabilities | 5,614 | 4,891 | ||
| Operating lease liability | 3,990 | 4,209 | ||
| Total liabilities | 9,604 | 9,100 | ||
| Common stock 0.001 par value 500,000,000 shares authorized 13,808,966 and 72,922 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 110 | 99 | ||
| Additional paid-in capital | 286,499 | 266,614 | ||
| Accumulated deficit | -269,217 | -260,189 | ||
| Total stockholders' equity | 17,392 | 6,524 | ||
| Total liabilities and stockholders' equity | 26,996 | 15,624 | ||
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)